Edwards Lifesciences (EW) Stock
Heart valve leader for critical care monitoring. Here's the price, business snapshot, and what's worth knowing about Edwards Lifesciences in October 2026.
Edwards Lifesciences Corporation (EW) is a medical-technology company focused on heart valves and critical-care monitoring. It is best known for the Sapien transcatheter aortic valve replacement (TAVR) system and a broad range of surgical valves and haemodynamic monitoring products. Investors typically monitor Edwards for its leadership in structural heart therapies, clinical-driven innovation, and exposure to an ageing population that boosts demand for valve procedures. Revenue growth is linked to procedure volumes, reimbursement environments and the success of clinical trials and new indications. The company invests in R&D and selective acquisitions to extend its portfolio and geographic reach. Key risks include competition, regulatory and reimbursement shifts, and sensitivity to elective-procedure cycles. This is general educational information only and not personalised financial advice; values can rise or fall and past performance is not a reliable guide. Consider your own circumstances or consult a financial adviser before making investment decisions.
Why It’s Moving
Edwards Lifesciences Secures FDA Approval for PASCAL Precision System in Tricuspid Valve Repair
- The FDA approved the PASCAL Precision system specifically for transcatheter edge-to-edge repair of the tricuspid valve.
- The device is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy.
- This approval expands Edwards Lifesciences' addressable market by targeting patients deemed appropriate for non-surgical intervention.
Edwards Lifesciences Secures FDA Approval for PASCAL Precision System in Tricuspid Valve Repair
- The FDA approved the PASCAL Precision system specifically for transcatheter edge-to-edge repair of the tricuspid valve.
- The device is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy.
- This approval expands Edwards Lifesciences' addressable market by targeting patients deemed appropriate for non-surgical intervention.
Sixth Month Growth Performance
When is the next earnings date for EDWARDS LIFESCIENCES CORP (EW)?
The next confirmed earnings date for Edwards Lifesciences (EW) is November 4, 2026, scheduled for after market close. This report will cover the company's third-quarter fiscal results for 2026. Investors should note that this timing aligns with the firm's historical pattern of reporting approximately three months after its previous July release.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Edwards Lifesciences stock with a target price of $91.56, indicating growth potential.
Financial Health
Edwards Lifesciences is performing well with strong revenue, profit margins, and cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Leader in TAVR
Edwards holds a strong position in transcatheter aortic valve replacement; adoption and expanded indications can support growth, though procedure volumes can fluctuate.
Clinical-driven innovation
Ongoing trials and new device launches are central to long-term prospects, but regulatory outcomes and trial timing can influence performance.
Demographics & reach
An ageing global population and geographic expansion present opportunities, while reimbursement and local regulation remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
